United States Respiratory Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

United States Respiratory Devices Market Trends and Insights

Rising COPD & Asthma Prevalence Among U.S. Adults

COPD affects 12.5 million diagnosed adults and asthma affects 26.8 million Americans, with prevalence peaking in southeastern and midwestern counties.^{[2]Source: Centers for Disease Control and Prevention, “Adults Diagnosed with COPD by County,” cdc.gov} State-level COPD rates vary from 3% in Hawaii to 12% in West Virginia, mirroring disparities in environmental exposures and healthcare access. COPD mortality spans 41–171 deaths per 100,000 adults, underscoring the ongoing therapeutic burden. These epidemiologic patterns fuel demand for nebulizers, oxygen concentrators, and digital inhalers capable of predicting exacerbations by monitoring inspiratory flow metrics. Annual direct and indirect asthma costs near USD 80 billion, intensifying payer interest in cost-effective home-based respiratory solutions.

Aging Demographics and Home-care Shift

Nearly one quarter of Americans will be 65 years or older by 2060, prompting a structural shift toward in-home therapy and remote patient monitoring. Medicare beneficiaries recorded over 240k COPD-related hospitalizations in recent times, amplifying the need for portable oxygen concentrators and home ventilators. Remote patient monitoring users already number about 50 million and are expected to double by the end of the decade as reimbursement aligns with value-based care incentives. The Patient-Driven Groupings Model increases operational complexity but rewards providers that demonstrate measurable outcome improvements using connected respiratory platforms. Long-term mechanical ventilation cases more than doubled over two decades, tightening capacity in post-acute facilities and driving investment in home-compatible ventilators.

CMS Reimbursement Expansion for Home Oxygen Therapy & NIV

New Healthcare Common Procedure Coding System (HCPCS) codes for multi-function respiratory devices effective January 2025 expand the eligible equipment roster and shorten payback periods for providers deploying advanced technology. While improper payment rates for CPAP accessories reached 15% in 2023, CMS has paired expanded coverage with stringent documentation audits to curb waste. The 2025 Physician Fee Schedule introduces a 2.93% reduction in average payment but preserves tele-health waivers that allow virtual evaluation of respiratory patients, sustaining hardware demand. Medicare Advantage plans must now include COPD and asthma in medication therapy management criteria, further broadening device access. The Home Health Value-Based Purchasing Model links reimbursement to outcome metrics, stimulating provider adoption of connected monitoring solutions that verify real-world efficacy.

Uptake of Smart, Connected Respiratory Devices via Tele-health

FDA clearance of AI-enabled lung sound analysis systems and home-use spirometers signals regulatory confidence in machine-learning diagnostics. ResMed’s NightOwl home sleep apnea test adds to a digital ecosystem that already serves 151 million patient lives through cloud-connected positive airway pressure (PAP) devices. Smart inhalers fitted with Bluetooth sensors deliver near-real-time adherence data and achieve up to 80% drug-delivery efficiency to the lungs, surpassing traditional inhalers. Wearable acoustic monitors in late-stage development will allow continuous assessment of trapped air and early detection of deterioration, and several have secured preliminary reimbursement codes ahead of full commercial launch. Emergency departments piloting AI scheduling tools report shorter waits for mechanical ventilation, illustrating downstream capacity gains from predictive device data.

High Up-front Cost & Hospital Capital Budget Cycles

Most U.S. hospitals allocate major equipment purchases once per fiscal year, extending replacement decisions 12–18 months and deferring acquisition of advanced ventilators and imaging-grade ultrasound devices. A 2.93% payment cut in the 2025 Physician Fee Schedule compresses operating margins, especially in rural facilities with thin cash reserves. Value-based reimbursement requires clear clinical-outcome evidence for capital requests, raising the bar for device makers to supply real-world data. Although COPD’s annual economic toll nears USD 50 billion, the longer payback period for sophisticated diagnostics can slow adoption, particularly where patient volumes are modest.^{[3]Source: American Lung Association, “National Indicator Report COPD,” lung.org} Manufacturers offer leasing and per-use subscription models to mitigate sticker shock, but uptake remains mixed outside large health systems.

Stringent FDA Approval Timelines

Average 510(k) review cycles for complex respiratory devices exceed 180 days, lengthening time-to-market and raising development costs. Breakthrough-device designation offers an expedited path but demands rigorous clinical evidence, a hurdle small innovators may struggle to meet. Post-market surveillance obligations have tightened after high-profile recalls, compelling companies to allocate extra resources to longitudinal safety studies. While stronger oversight improves patient protection, it can delay commercialization of incremental innovations such as AI software updates embedded in existing hardware. Some firms have adopted modular regulatory strategies, securing clearance for core platforms first and layering software features under subsequent supplements.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Therapeutic Dominance Amid Diagnostic Acceleration

Therapeutic devices commanded 46.10% of the 2025 United States respiratory devices market, anchored by positive airway pressure (PAP) systems and home ventilators that address both chronic and acute conditions. The installed base generates high-margin consumables demand, while AI-driven adherence algorithms elevate therapeutic efficacy. Diagnostic & monitoring devices remain the fastest-growing category at a 6.42% CAGR through 2031 as FDA-cleared home-use spirometers and AI auscultation software migrate testing from clinics to living rooms. Disposables retain steady uptake because masks, filters, and breathing circuits require periodic replacement, ensuring recurring revenue.

A key growth inflection stems from vibrating mesh nebulizers that deliver superior deposition in COPD therapy, prompting formulary inclusion by major payers. Portable oxygen concentrators integrate cloud connectivity, allowing clinicians to titrate flow remotely and aligning with home-care trends. Diagnostic smart patches that track respiratory rate and sleep motion shorten sleep–apnea diagnosis cycles. Combined, these factors add incremental value to the United States respiratory devices market size while intensifying competition around data-driven user experiences.

By Indication: COPD Scale Meets Sleep-Apnea Momentum

COPD represented 43.80% of the United States respiratory devices market size in 2025, as 12.5 million adults required ongoing ventilatory support, nebulization, and oxygen therapy. Hospitalizations among Medicare beneficiaries reinforce device turnover in institutional settings and extend demand into skilled nursing facilities. Sleep apnea is accelerating at an 8.45% CAGR to 2031, propelled by insurer acceptance of home sleep tests and strong evidence that CPAP therapy lowers all-cause mortality. Asthma, with an 8.2% prevalence, continues to drive inhaler and peak-flow meter volume, especially for pediatric care.

Infectious respiratory diseases temporarily lifted ventilator utilization during COVID-19 surges, normalizing at higher baseline levels than pre-pandemic as hospitals maintain contingency stock. Other disorders—including bronchiectasis and neuromuscular-related hypoventilation—contribute a niche but stable demand for airway-clearance devices and volume-guaranteed ventilators. Precise segmentation allows suppliers to tailor accessories, such as specialized masks for the pediatric sleep-apnea cohort, thereby expanding the addressable share without cannibalizing core COPD revenue.

By End User: Home-care Momentum Reshapes Distribution

Hospitals and clinics held 54.75% of United States respiratory devices market share in 2025 courtesy of critical-care ventilator fleets, pulmonary function labs, and anesthesia departments. Yet home-care settings register the highest 7.45% CAGR as payers steer chronic-disease management away from costly inpatient environments. Remote patient monitoring platforms feed continuous flow, saturation, and usage data directly into electronic health records, supporting value-based reimbursement triggers. Ambulatory surgical centers prefer compact ventilators that integrate capnography to streamline outpatient sedation workflows, mirroring the broader shift toward minimally invasive procedures.

Long-term-care facilities increase procurement of pressure-support ventilators and suction units as the number of patients needing prolonged respiratory assistance climbs. Emergency and trauma centers diversify inventory with high-flow nasal oxygen systems and portable ECMO readiness kits to buffer against mass-casualty respiratory events. Collectively, these dynamics realign distribution networks, prompting manufacturers to strike partnerships with durable-medical-equipment suppliers to reach patients wherever they receive care

Geography Analysis

The South led with 31.95% of the United States respiratory devices market in 2025, reflecting elevated COPD prevalence that peaks at 12% in West Virginia compared with 3% in Hawaii. High air-conditioning use elevates indoor humidity control needs, influencing the selection of dehumidifying oxygen concentrators. The region’s robust hospital networks and sizable long-term-care footprint underpin replacement cycles for ventilators and suction gear.

The West posts the strongest 7.90% CAGR to 2031 as wildfire smoke drives consumer adoption of HEPA-equipped respiratory devices and as technology-forward health systems embrace AI-enabled home diagnostics. Indoor air-filtration can halve particulate exposure during smoke events, encouraging insurers to underwrite purifiers for high-risk members. Tech hubs in California and Washington foster early trials of connected inhalers and acoustic wearables, accelerating commercial uptake.

The Northeast benefits from higher per-capita healthcare spending and early adoption of digital-health solutions; academic medical centers there often pioneer AI respiratory algorithms. The Midwest balances industrial air-quality challenges with agricultural dust exposure, sustaining steady device replacement demand. Meanwhile, the Southwest faces dust-storm respiratory risks that raise filtration and nebulizer purchases among vulnerable groups. Across all regions, CMS reimbursement for home oxygen and non-invasive ventilation narrows rural–urban gaps, allowing patients in remote counties to access advanced devices without traveling long distances for care.

Regulatory Landscape

Respiratory devices and respiratory drug-device combination products in the United States are regulated by the US Food and Drug Administration (FDA), with the Office of Combination Products (OCP) assigning product jurisdiction based on the primary mode of action under 21 CFR Part 3. For combination products such as inhalation therapies delivered through device platforms, manufacturers must align development, labeling, and postmarket controls to the lead center (CDER, CDRH, or CBER) while meeting applicable requirements across both drug and device frameworks.

Quality and safety compliance for combination products is anchored in 21 CFR Part 4, which integrates device Quality System requirements with drug CGMP expectations and adds postmarketing safety reporting obligations (21 CFR Part 4, Subpart B) that connect to FDA safety reporting systems (FAERS and eMDR). Alongside FDA oversight, 2026 trade-policy activity increased attention on medical equipment supply chains, including the USTR 2026 Trade Policy Agenda and July 2026 American Hospital Association comments opposing proposed tariffs on imported medical devices due to concerns about clinical access and cost pressures.

Value Chain Analysis

The US respiratory devices value chain runs from upstream material and component suppliers (plastics, elastomers, sensors, micro-blowers, filtration media, batteries, and electronics) through device OEM engineering, software and connectivity development, and validation/testing aligned to FDA expectations for respiratory devices and combination products. For inhalation combination products, it also includes drug substance and excipient manufacturing, formulation and filling, device component fabrication (actuators, canisters, DPIs, nebulizer interfaces), and final assembly and packaging under integrated quality systems. FDA OCP jurisdiction decisions (PMOA) further shape whether a program follows device pathways (510(k), De Novo, PMA) or drug pathways (NDA/ANDA, including 505(b)(2) strategies where applicable).

Contract manufacturing and development partners can be central for scaling respiratory platforms, especially when drug, device, and final assembly steps are split across multiple entities and require unified quality agreements, change control, and inspection readiness. Distribution typically flows through hospital and clinic procurement, durable medical equipment (DME) and home-care providers, including oxygen and PAP supply networks, and increasingly through digital channels that support remote setup, adherence monitoring, and replenishment of consumables. Consolidation among component and manufacturing specialists remains a lever for tightening lead times and controlling compliance risk, exemplified by Molex LLC's January 2025 acquisition of Vectura Group Ltd to broaden inhalation and combination product development capabilities.

Market Opportunities and Future Outlook

In the United States respiratory devices market, opportunities tend to concentrate where home-care expansion, documentation-driven reimbursement, and connected-care workflows overlap. CMS actions, including the January 2025 effective HCPCS codes for multi-function respiratory devices, support provider economics for advanced home oxygen and non-invasive ventilation deployments. At the same time, growing audit intensity raises the value of devices that capture objective usage and performance data to support claims and value-based outcome reporting.

Product white space also appears in low-effort delivery and adherence-enabling inhalation systems designed to reduce coordination errors in chronic therapy, as well as in sensor-enabled nebulization and ventilation platforms that support remote titration and monitoring. Regulatory throughput and recent clearances reinforce this direction, including June 2026 510(k) clearance for FindAir ONE for pMDI (a direct patient interface nebulizer) and February 2026 510(k) clearance for a non-invasive ventilation device with integrated sensors. On the drug-device side, May 2025 FDA approval of Liquidia's YUTREPIA (treprostinil) inhalation powder highlights continued commercialization pathways for inhaled combination therapies that pair particle engineering with dedicated delivery formats, broadening the set of respiratory indications and care settings.